Biomarkers for Cognitive Impairment in Parkinson Disease
Identifieur interne : 000798 ( Main/Exploration ); précédent : 000797; suivant : 000799Biomarkers for Cognitive Impairment in Parkinson Disease
Auteurs : Min Shi ; Bertrand R. Huber ; Jing ZhangSource :
- Brain Pathology [ 1015-6305 ] ; 2010-05.
English descriptors
- KwdEn :
Abstract
Cognitive impairment, including dementia, is commonly seen in those afflicted with Parkinson disease (PD), particularly at advanced disease stages. Pathologically, PD with dementia (PD‐D) is most often associated with the presence of cortical Lewy bodies, as is the closely related dementia with Lewy bodies (DLB). Both PD‐D and DLB are also frequently complicated by the presence of neurofibrillary tangles and amyloid plaques, features most often attributed to Alzheimer disease. Biomarkers are urgently needed to differentiate among these disease processes and predict dementia in PD as well as monitor responses of patients to new therapies. A few clinical assessments, along with structural and functional neuroimaging, have been utilized in the last few years with some success in this area. Additionally, a number of other strategies have been employed to identify biochemical/molecular biomarkers associated with cognitive impairment and dementia in PD, e.g. targeted analysis of candidate proteins known to be important to PD pathogenesis and progression in cerebrospinal fluid or blood. Finally, interesting results are emerging from preliminary studies with unbiased and high throughput genomic, proteomic and metabolomic techniques. The current findings and perspectives of applying these strategies and techniques are reviewed in this article, together with potential areas of advancement.
Url:
DOI: 10.1111/j.1750-3639.2009.00370.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers for Cognitive Impairment in Parkinson Disease</title><author><name sortKey="Shi, Min" sort="Shi, Min" uniqKey="Shi M" first="Min" last="Shi">Min Shi</name></author><author><name sortKey="Huber, Bertrand R" sort="Huber, Bertrand R" uniqKey="Huber B" first="Bertrand R." last="Huber">Bertrand R. Huber</name></author><author><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1886F176974A285C3BD65580B868B89BBD603582</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1750-3639.2009.00370.x</idno><idno type="url">https://api.istex.fr/document/1886F176974A285C3BD65580B868B89BBD603582/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000303</idno><idno type="wicri:Area/Main/Curation">000256</idno><idno type="wicri:Area/Main/Exploration">000798</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biomarkers for Cognitive Impairment in Parkinson Disease</title><author><name sortKey="Shi, Min" sort="Shi, Min" uniqKey="Shi M" first="Min" last="Shi">Min Shi</name><affiliation><wicri:noCountry code="subField">Wa</wicri:noCountry></affiliation></author><author><name sortKey="Huber, Bertrand R" sort="Huber, Bertrand R" uniqKey="Huber B" first="Bertrand R." last="Huber">Bertrand R. Huber</name><affiliation><wicri:noCountry code="subField">Wa</wicri:noCountry></affiliation></author><author><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name><affiliation><wicri:noCountry code="subField">Wa</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Pathology</title><idno type="ISSN">1015-6305</idno><idno type="eISSN">1750-3639</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-05">2010-05</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="660">660</biblScope><biblScope unit="page" to="671">671</biblScope></imprint><idno type="ISSN">1015-6305</idno></series><idno type="istex">1886F176974A285C3BD65580B868B89BBD603582</idno><idno type="DOI">10.1111/j.1750-3639.2009.00370.x</idno><idno type="ArticleID">BPA370</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1015-6305</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>biomarker</term><term>cerebrospinal fluid</term><term>dementia</term><term>genomics</term><term>metabolomics</term><term>mild cognitive impairment</term><term>proteomics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment, including dementia, is commonly seen in those afflicted with Parkinson disease (PD), particularly at advanced disease stages. Pathologically, PD with dementia (PD‐D) is most often associated with the presence of cortical Lewy bodies, as is the closely related dementia with Lewy bodies (DLB). Both PD‐D and DLB are also frequently complicated by the presence of neurofibrillary tangles and amyloid plaques, features most often attributed to Alzheimer disease. Biomarkers are urgently needed to differentiate among these disease processes and predict dementia in PD as well as monitor responses of patients to new therapies. A few clinical assessments, along with structural and functional neuroimaging, have been utilized in the last few years with some success in this area. Additionally, a number of other strategies have been employed to identify biochemical/molecular biomarkers associated with cognitive impairment and dementia in PD, e.g. targeted analysis of candidate proteins known to be important to PD pathogenesis and progression in cerebrospinal fluid or blood. Finally, interesting results are emerging from preliminary studies with unbiased and high throughput genomic, proteomic and metabolomic techniques. The current findings and perspectives of applying these strategies and techniques are reviewed in this article, together with potential areas of advancement.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Huber, Bertrand R" sort="Huber, Bertrand R" uniqKey="Huber B" first="Bertrand R." last="Huber">Bertrand R. Huber</name><name sortKey="Shi, Min" sort="Shi, Min" uniqKey="Shi M" first="Min" last="Shi">Min Shi</name><name sortKey="Zhang, Jing" sort="Zhang, Jing" uniqKey="Zhang J" first="Jing" last="Zhang">Jing Zhang</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000798 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000798 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1886F176974A285C3BD65580B868B89BBD603582
|texte= Biomarkers for Cognitive Impairment in Parkinson Disease
}}
| This area was generated with Dilib version V0.6.23. |  |